Great Lakes Breast Cancer Research Symposium

This conference has already taken place.

The sixth annual Great Lakes Breast Cancer Research Symposium will highlight ongoing basic, translational, clinical, and population research, focusing on risk factors, outcomes, survivorship; tumor cell biology; cancer biomarkers; immuno-oncology and molecularly-targeted diagnostics and therapeutics. The mission of the symposium is to bring together a diverse audience to create a collaborative research environment with a long-term goal of developing cross-institutional collaborations, clinical trials, and treatments for breast cancer.

NOTE: Session 1 - Risk Factors, Outcomes, and Survivorship - will convene at the Blackwell Inn, 2110 Tuttle Park Place, on The Ohio State University campus.

For pricing information, see pricing tab below.

• Additional Info
• Agenda
• Pricing
• Speakers
• Location
• Accreditation & Credit Statements

Dates and Times

Start: 10/27/2024 1:00 PM
End: 10/29/2024 2:00 PM

Objectives

At the conclusion of this continuing medical education activity participants should be able to:

1. Promote networking amongst clinical providers and members of the pharmaceutical and biotech industries which will lead to new research collaborators.
2. Aid researchers in identifying patient populations that will benefit from the further development of cancer therapeutics or other inventions.
3. Integrate recent data and employ the finding as they seek to optimize different therapies available for breast cancer patients.
4. Describe best practices for symptom management related to breast cancer and its treatment side effects.

Agenda

Pricing

Tier	Price
Physician	$200.00
Advanced Practice Providers/Nurse Practitioners	$200.00
PhD	$200.00
Resident/Fellow	$100.00
Trainee/Student	$100.00
Commercial Representative	$200.00
Patient Advocate	$0.00

Speakers

• Marija Balic, MD
  • Liquid Biopsy in Breast Cancer Patients with Metastatic Hormone Receptor Positive Disease
• Noah Carrillo, Doctoral Degree
  • 3rd Messengers: Nuclear Phosphoinositide Signaling in Cancer
• William Carson, MD
  • Inhibition of Immune Suppressor Cells to Enhance Therapy of Triple-Negative Breast Cancer
• Yong Chen, PhD
  • Predicting Early Response to Neoadjuvant Chemotherapy in Breast Cancer Using Magnetic Resonance Fingerprinting
• Erin Cobain, MD
  • Novel Biomarkers Predictive of Immunotherapy Benefit
• Susan Domchek, MD
  • KEYNOTE: Breast Cancer and Genomic Medicine: Risk to Interception
• Julia Foldi, MD
  • Mixed Molecular Subtypes Exist in Estrogen Receptor-Heterogenous Primary Breast Cancers
• Steven Frisch, PhD
  • Grainyhead-Like-2, an Epithelial Master Programmer, Promotes Interferon Induction and Prevents Breast Cancer Recurrence
• Kokeb Gebremeskel, Master's Degree
  • Magnetic Resonance Imaging of Microfluidics Breast Tumor Model Using Newly Designed Controlled Heating Apparatus (CHAMP-3)
• Treg Grubb, PhD
  • Glucocorticoids Block Hypoxia-Induced Mesenchymal Programs in Triple-Negative Breast Cancer
• Norah Henry, MD
  • AIMing to Improve Quality of Life in Aromatase Inhibitor-Treated Patients
• Natasha Ingles, Bachelor Degree
  • YES1 is a Core Regulator of Stem/Progenitor Cells in Triple-Negative Breast Cancer
• Ruth Keri, PhD
  • YES1 Regulation of Breast Cancer Therapeutic Response
• Megan Kruse, MD
  • Targeted Therapy for Invasive Lobular Cancer- Current Approaches and Future Directions
• Dhanaji Lade, PhD
  • Developing SHP2 Targeting Covalent Active Site Inhibitors and Testing Efficacy as Anti-Breast Cancer Agents Dhanaji Lade, PhD
• Paul Lockman, PhD
  • The Blood-Brain Barrier is an Impediment in the Treatment of Brain Metastases
• Gary Luker, MD
  • Social Interactions Between Breast Cancer and Stromal Cells
• Daniel McGrail, PhD
  • Distinct Drivers of Immune Checkpoint Blockade Sensitivity in Breast Cancer
• Alexis Mossing, Bachelor Degree
  • Immunomodulation of the Primary Breast Tumor Microenvironment by PDGFB
• Josh Newby, Bachelor Degree
  • Introduction to the 2025 Metastatic Breast Cancer / GLBCRS Meeting
• Samilia Obeng-Gyasi, MD
  • The Role of Allostatic Load and Epigenetics in Breast Cancer
• Andrew Orenberg, Bachelor Degree
  • An Unconventional Role of Actin-Binding Protein Profilin1 in Phospholipid Maintenance in Cancer Cells
• Electra Paskett, Other
  • Increasing Cancer Screening Among Rural Women: The RISE Study
• Eduardo Reategui, PhD
  • Decoding Vesicular Protein and RNA Signatures from Complex Biofluids for Cancer Detection
• Kathryn Schmitz, PhD
  • Exercise Intervention in Older Women Receiving Chemotherapy for Early-Stage Breast Cancers and How that Affects Chemotherapy Dose Intensity
• Emily Schwarz, Bachelor Degree
  • Trabectedin Enhances IL-12 Anti-Tumor Immunity in Triple-Negative Breast Cancer
• Habib Serhan, Bachelor Degree
  • Targeting Fatty Acid Synthase in Preclinical Models of Triple-Negative Breast Cancer Brain Metastases
• Gina Sizemore, PhD
  • PDGFB Promotes Brain Metastasis Through Myeloid Lineage Modulation
• Mark Slayton, PhD
  • Malic Enzyme 2 Contributes to Metabolite Production, Survival, and Metastasis in Triple-Negative Breast Cancer
• Khalid Sossey Aaloui, PhD
  • The Small Molecule Inhibitor SU056 as a Novel Therapeutic Agent to Target TNBC Tumors
• Wayne Stallaert, PhD
  • Cell Cycle Mapping and Plasticity
• Abdalla Wedn, Master's Degree
  • Hypomethylation and Over-Expression of AP2B in ILC Causes Increased Growth Due to Effects on Cell Cycle
• Alana Welm, PhD
  • KEYNOTE: Modeling Metastatic Breast Cancer to Advance Therapeutic Strategies
• Michelle Williams, PhD
  • Revealing Molecular Vulnerabilities via Immune Phenotypes in Breast Cancer Liver Metastasis
• Wei Xu, PhD
  • Model ER+ Metastatic Breast Cancer in Rats

Location

Vitria On the Square
14 E. 15th Avenue
Columbus, OH 43201

Accreditation Statement

The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Ohio State University designates this live activity for a maximum of 16.50 AMA PRA Category 1 Credit(s) ^™. Physicians should only claim credit commensurate with the extent of their participation in the activity.